48 listed pharmaceutical companies report their achievements
After the annual report release tide of global large multinational pharmaceutical enterprises, the industry recently ushered in the annual report intensive disclosure period of local pharmaceutical listed enterprises. According to Dongfang wealth choice data, as of March 28, 48 pharmaceutical enterprises belonging to the two major sectors of pharmaceutical manufacturing and medical treatment successively published their 2019 annual reports. Among them, the performance of the vast majority of enterprises has turned red.
At present, Shanghai Pharmaceutical Co., Ltd. leads with revenue of 186.6 billion yuan, and Hengrui Pharmaceutical Co., Ltd. has the highest net profit of 5.328 billion yuan. However, in terms of the year-on-year growth of revenue, there are also six enterprises regretting "floating green", and pharmaceutical enterprises such as Asia Pacific pharmaceutical and Shutai Shen are at the forefront of the drop list. Dominating the group: Hengrui leads the way in terms of net profit. The proportion of R & D expenses is in line with that of Hengrui pharmaceutical. The company's first report card after sun piaoyan, its founder and chairman, leaves office. In 2019, the company's revenue is 23.3 billion yuan, with a year-on-year growth of 33.7% and a net profit of 5.328 billion yuan, which is enough to dominate the group.
As the local "first brother of medicine" with a total market value of more than 400 billion yuan, Hengrui pharmaceutical has always attracted external attention due to the driving factors of its performance growth. In general, the following two points can be said to be the biggest pillar of Hengrui's performance growth. During the reporting period, carrizumab and rimazolom toluenesulfonate of Hengrui medicine were approved for listing, pyrrolidine maleate tablets and tiopefigeristine were first introduced into the medical insurance through negotiation, apatinib and pemendonase injections were successfully continued, and innovative drugs "fruits" continued to be harvested.
2026-10-13
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Domestic substitution is the most difficult one
-
The Development Status Of Pharmaceutical Companies In India
-
New Trend of Multinational Pharmaceutical Companies in China? AstraZeneca Fully Enters Chinese Medicine
-
Top Biotechnology Financing List Released! Two Chinese Pharmaceutical Companies Make The List
-
2021 Global Pharmaceutical Company Revenue TOP20 Announced!
-
Changes and trends in the global drug R&D pipeline in 2021
-
Market Analysis - Annual Report -April, 2020- Sulfamonomethoxine Sodium
-
Market Analysis - Annual Report -April, 2020- Tiamulin Fumarate
-
Which pharma companies are the most innovative? Roche, AstraZeneca top the list
-
LG Chem Teams Up with Jianghua Microelectronics to Advance Semiconductor Ultra-High-Purity IPA
Recommend Reading
-
Kemira Acquires AquaBlue
-
Sherwin-Williams Opens High-Performance Industrial Coatings Facility in Saskatchewan
-
South Korea to Impose Anti-Dumping Duties on Caustic Soda: Chinese Mainland Firms Face Up to 22.21%, Taiwan Region 38.89%
-
Trump’s Steel, Aluminum and Copper Tariff Changes Pull Chemical Manufacturing Into the Impact Zone
-
Honeywell Acquires Johnson Matthey Catalyst Business at a Discount, Cutting £475 Million from the Price
-
Positive Factors Concentratedly Released, Acetone Market Strongly Rises After the Holiday
-
Business Society’s Trend Analysis for Fuel Oil 180CST on September 14, 2026: Volatile Fluctuations
-
Business Society September 14, 2026 MTBE Trend Analysis: Strong Consolidation
-
Business Society September 23, 2026 Heavy-Grade Soda Ash Trend Analysis: A Short-Side Rally
-
Cost-side positives boost polyester staple fiber prices, ushering in a rebound